Endoscopic Submucosal Dissection Followed by Chemoradiotherapy Versus Radiotherapy in Patients with Stage T1bN0M0 Esophageal Cancer.

IF 1.6 Q4 ONCOLOGY

Journal of Gastrointestinal Cancer Pub Date : 2025-07-11 DOI:10.1007/s12029-025-01270-4

Yan Lin, Cheng-Xian Ma, Huan-Wei Liang, Wei Huang, Xin-Bin Pan

{"title":"Endoscopic Submucosal Dissection Followed by Chemoradiotherapy Versus Radiotherapy in Patients with Stage T1bN0M0 Esophageal Cancer.","authors":"Yan Lin, Cheng-Xian Ma, Huan-Wei Liang, Wei Huang, Xin-Bin Pan","doi":"10.1007/s12029-025-01270-4","DOIUrl":null,"url":null,"abstract":"Purpose: To compare survival outcomes between endoscopic submucosal dissection (ESD) followed by chemoradiotherapy versus radiotherapy in stage T1bN0M0 esophageal cancer.Materials and methods: Patients with stage T1bN0M0 esophageal cancer between 2000 and 2021 were identified from the Surveillance, Epidemiology, and End Results database. Cancer-specific survival (CSS) and overall survival (OS) were compared between the ESD followed by chemoradiotherapy versus radiotherapy cohorts.Results: Among 71 eligible patients, 57 (80.3%) received ESD followed by chemoradiotherapy and 14 (19.7%) underwent ESD followed by radiotherapy. Before propensity score matching, ESD followed by radiotherapy demonstrated inferior 5-year CSS (hazard ratio [HR] = 3.27, 95% confidence interval [CI] 1.12-9.58, P = 0.030), but comparable 5-year OS (HR = 1.46; 95% CI, 0.65-3.27; P = 0.362) versus ESD followed by chemoradiotherapy. After propensity score matching, no significant difference in 5-year CSS (HR = 1.76; 95% CI, 0.49-6.34; P = 0.386) or OS (HR = 1.33; 95% CI, 0.48-3.74; P = 0.585) was observed between treatment groups.Conclusion: ESD followed by radiotherapy provides equivalent CSS and OS compared to ESD followed by chemoradiotherapy in patients with stage T1bN0M0 esophageal cancer.","PeriodicalId":15895,"journal":{"name":"Journal of Gastrointestinal Cancer","volume":"56 1","pages":"150"},"PeriodicalIF":1.6000,"publicationDate":"2025-07-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Gastrointestinal Cancer","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1007/s12029-025-01270-4","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"ONCOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Purpose: To compare survival outcomes between endoscopic submucosal dissection (ESD) followed by chemoradiotherapy versus radiotherapy in stage T1bN0M0 esophageal cancer.

Materials and methods: Patients with stage T1bN0M0 esophageal cancer between 2000 and 2021 were identified from the Surveillance, Epidemiology, and End Results database. Cancer-specific survival (CSS) and overall survival (OS) were compared between the ESD followed by chemoradiotherapy versus radiotherapy cohorts.

Results: Among 71 eligible patients, 57 (80.3%) received ESD followed by chemoradiotherapy and 14 (19.7%) underwent ESD followed by radiotherapy. Before propensity score matching, ESD followed by radiotherapy demonstrated inferior 5-year CSS (hazard ratio [HR] = 3.27, 95% confidence interval [CI] 1.12-9.58, P = 0.030), but comparable 5-year OS (HR = 1.46; 95% CI, 0.65-3.27; P = 0.362) versus ESD followed by chemoradiotherapy. After propensity score matching, no significant difference in 5-year CSS (HR = 1.76; 95% CI, 0.49-6.34; P = 0.386) or OS (HR = 1.33; 95% CI, 0.48-3.74; P = 0.585) was observed between treatment groups.

Conclusion: ESD followed by radiotherapy provides equivalent CSS and OS compared to ESD followed by chemoradiotherapy in patients with stage T1bN0M0 esophageal cancer.

查看原文本刊更多论文

T1bN0M0期食管癌患者的内镜下粘膜剥离术后放化疗与放疗比较。

目的：比较内镜下粘膜下剥离（ESD）联合放化疗与放疗对T1bN0M0期食管癌患者的生存结果。材料和方法：从监测、流行病学和最终结果数据库中确定2000年至2021年间T1bN0M0期食管癌患者。比较ESD后放化疗组和放疗组的癌症特异性生存期（CSS）和总生存期（OS）。结果：71例符合条件的患者中，57例（80.3%）接受ESD +放化疗，14例（19.7%）接受ESD +放疗。倾向评分匹配前，ESD后放疗的5年CSS较差（风险比[HR] = 3.27, 95%可信区间[CI] 1.12-9.58, P = 0.030），但5年OS较差(HR = 1.46；95% ci, 0.65-3.27；P = 0.362)与ESD后放化疗相比。倾向评分匹配后，5年CSS差异无统计学意义(HR = 1.76；95% ci, 0.49-6.34；P = 0.386)或OS (HR = 1.33；95% ci, 0.48-3.74；P = 0.585)。结论：对于T1bN0M0期食管癌患者，与ESD +放化疗相比，ESD +放疗可提供相当的CSS和OS。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Journal of Gastrointestinal Cancer ONCOLOGY-

CiteScore

3.80

自引率

0.00%

发文量

121

期刊介绍： The Journal of Gastrointestinal Cancer is a multidisciplinary medium for the publication of novel research pertaining to cancers arising from the gastrointestinal tract.The journal is dedicated to the most rapid publication possible.The journal publishes papers in all relevant fields, emphasizing those studies that are helpful in understanding and treating cancers affecting the esophagus, stomach, liver, gallbladder and biliary tree, pancreas, small bowel, large bowel, rectum, and anus. In addition, the Journal of Gastrointestinal Cancer publishes basic and translational scientific information from studies providing insight into the etiology and progression of cancers affecting these organs. New insights are provided from diverse areas of research such as studies exploring pre-neoplastic states, risk factors, epidemiology, genetics, preclinical therapeutics, surgery, radiation therapy, novel medical therapeutics, clinical trials, and outcome studies.In addition to reports of original clinical and experimental studies, the journal also publishes: case reports, state-of-the-art reviews on topics of immediate interest or importance; invited articles analyzing particular areas of pancreatic research and knowledge; perspectives in which critical evaluation and conflicting opinions about current topics may be expressed; meeting highlights that summarize important points presented at recent meetings; abstracts of symposia and conferences; book reviews; hypotheses; Letters to the Editors; and other items of special interest, including:Complex Cases in GI Oncology: This is a new initiative to provide a forum to review and discuss the history and management of complex and involved gastrointestinal oncology cases. The format will be similar to a teaching case conference where a case vignette is presented and is followed by a series of questions and discussion points. A brief reference list supporting the points made in discussion would be expected.